Synergistic Action of Phage and Antibiotics: Parameters to Enhance the Killing Efficacy Against Mono and Dual-Species Biofilms
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Pseudomonas aeruginosa and Staphylococcus aureus are opportunistic pathogens and are commonly found in polymicrobial biofilm-associated diseases, namely chronic wounds. Their co-existence in a biofilm contributes to an increased tolerance of the biofilm to antibiotics. Combined treatments of bacteriophages and antibiotics have shown a promising antibiofilm activity, due to the profound differences in their mechanisms of action. In this study, 48 h old mono and dual-species biofilms were treated with a newly isolated P. aeruginosa infecting phage (EPA1) and seven different antibiotics (gentamicin, kanamycin, tetracycline, chloramphenicol, erythromycin, ciprofloxacin, and meropenem), alone and in simultaneous or sequential combinations. The therapeutic efficacy of the tested antimicrobials was determined. Phage or antibiotics alone had a modest effect in reducing biofilm bacteria. However, when applied simultaneously, a profound improvement in the killing effect was observed. Moreover, an impressive biofilm reduction (below the detection limit) was observed when gentamicin or ciprofloxacin were added sequentially after 6 h of phage treatment. The effect observed does not depend on the type of antibiotic but is influenced by its concentration. Moreover, in dual-species biofilms it was necessary to increase gentamicin concentration to obtain a similar killing effect as occurs in mono-species. Overall, combining phages with antibiotics can be synergistic in reducing the bacterial density in biofilms. However, the concentration of antibiotic and the time of antibiotic application are essential factors that need to be considered in the combined treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MEME SUITE: tools for motif discovery and searching
Bailey, T. L., Boden, M., Buske, F. A., Frith, M., Grant, C. E., Clementi, L., Ren, J., Li, W. W., & Noble, W. S. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp335 · Cited by 10,648 · cited 1×
“[50] Transcriptional factors were determined by MEME [51] and ARNold [52] for the promoter and rho-independent terminators, respectively.”
MethodImproved Prediction of Signal Peptides: SignalP 3.0
Dyrløv Bendtsen, J., Nielsen, H., von Heijne, G., & Brunak, S. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.05.028 · Cited by 6,350
Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria
Hall, C. W., & Mah, T.-F. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux010 · Cited by 1,696
Pastar, I., Nusbaum, A. G., Gil, J., Patel, S. B., Chen, J., Valdes, J., Stojadinovic, O., Plano, L. R., Tomic-Canic, M., & Davis, S. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056846 · Cited by 391 · cited 1×
“These biofilms very often exhibit improved capabilities and functions compared to single-species ones [5,6], such as enhanced degradation of organic compounds [7], increased virulence [8], and increased tolerance against antimicrobials [9].”
BackgroundIn vivo and In vitro Interactions between Pseudomonas aeruginosa and Staphylococcus spp.
Hotterbeekx, A., Kumar-Singh, S., Goossens, H., & Malhotra-Kumar, S. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00106 · Cited by 289
Cited by
Gu Liu, C., Green, S. I., Min, L., Clark, J. R., Salazar, K. C., Terwilliger, A. L., Kaplan, H. B., Trautner, B. W., Ramig, R. F., & Maresso, A. W. (2020) · mBio · doi:10.1128/mbio.01462-20 · Cited by 409
Considerations for the Use of Phage Therapy in Clinical Practice
Suh, G. A., Lodise, T. P., Tamma, P. D., Knisely, J. M., Alexander, J., Aslam, S., Barton, K. D., Bizzell, E., Totten, K. M. C., Campbell, J. L., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02071-21 · Cited by 378
Current challenges and future opportunities of phage therapy
Pires, D. P., Costa, A. R., Pinto, G., Meneses, L., & Azeredo, J. (2020) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaa017 · Cited by 340
Self-citationShariati, A., Arshadi, M., Khosrojerdi, M. A., Abedinzadeh, M., Ganjalishahi, M., Maleki, A., Heidary, M., & Khoshnood, S. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1025633 · Cited by 337
Bacteriophage therapy against Pseudomonas aeruginosa biofilms: a review
Chegini, Z., Khoshbayan, A., Taati Moghadam, M., Farahani, I., Jazireian, P., & Shariati, A. (2020) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-020-00389-5 · Cited by 321
Metadata
- Authors
- Akturk, E., Oliveira, H., Santos, S. B., Costa, S., Kuyumcu, S., Melo, L. D. R., & Azeredo, J.
- Venue
- Antibiotics
- Publisher
- MDPI AG
- Published
- 2019-07-25
- Volume
- 8
- Issue
- 3
- Pages
- 103
- ISSN
- 2079-6382 (ISSN-L)
- OpenAlex
- W2963246688
- Cited by
- 172
- References
- 5
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.